Cargando…

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Glioblastoma (GB) is the most common and aggressive primary brain tumor in adults and currently incurable. Despite multimodal treatment regimens, median survival in unselected patient cohorts is <1 year, and recurrence remains almost inevitable. Escape from immune surveillance is thought to contr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burger, Michael C., Zhang, Congcong, Harter, Patrick N., Romanski, Annette, Strassheimer, Florian, Senft, Christian, Tonn, Torsten, Steinbach, Joachim P., Wels, Winfried S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6868035/ https://www.ncbi.nlm.nih.gov/pubmed/31798595 http://dx.doi.org/10.3389/fimmu.2019.02683

Ejemplares similares

CD19‐CAR engineered NK‐92 cells are sufficient to overcome NK cell resistance in B‐cell malignancies
por: Romanski, Annette, et al.
Publicado: (2016)

ErbB2/Her2-specific NK cells for adoptive immunotherapy of glioblastoma
por: Zhang, Congcong, et al.
Publicado: (2014)

AAV-mediated gene transfer of a checkpoint inhibitor in combination with HER2-targeted CAR-NK cells as experimental therapy for glioblastoma
por: Strecker, M.I., et al.
Publicado: (2022)

Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
por: Eitler, Jiri, et al.
Publicado: (2021)

ErbB2/HER2-specific NK cells for adoptive cancer immunotherapy
por: Zhang, Congcong, et al.
Publicado: (2013)

Arming NK cells with enhanced antitumor activity: CARs and beyond
por: Oberoi, Pranav, et al.
Publicado: (2013)

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity
por: Zhang, Congcong, et al.
Publicado: (2017)

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer
por: Murali Shankar, Nivedha, et al.
Publicado: (2023)

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
por: Burger, Michael C, et al.
Publicado: (2023)

“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
por: Mitwasi, Nicola, et al.
Publicado: (2020)

Innate-like NKp30(+)CD8(+) T cells armed with TCR/CAR target tumor heterogeneity
por: Correia, Margareta P., et al.
Publicado: (2021)

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma
por: Heim, Catrin, et al.
Publicado: (2023)

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers
por: Pfeifer Serrahima, Jordi, et al.
Publicado: (2023)

Co-Expression of an IL-15 Superagonist Facilitates Self-Enrichment of GD(2)-Targeted CAR-NK Cells and Mediates Potent Cell Killing in the Absence of IL-2
por: Bodden, Malena, et al.
Publicado: (2023)

NKG2C+ NK Cells for Immunotherapy of Glioblastoma Multiforme
por: Murad, Shafiq, et al.
Publicado: (2022)

CAR-NK cell therapy for glioblastoma: what to do next?
por: Xiong, Qi, et al.
Publicado: (2023)

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma
por: Merker, Michael, et al.
Publicado: (2020)

Realizing Innate Potential: CAR-NK Cell Therapies for Acute Myeloid Leukemia
por: Gurney, Mark, et al.
Publicado: (2021)

Akt and mTORC1 signaling as predictive biomarkers for the EGFR antibody nimotuzumab in glioblastoma
por: Ronellenfitsch, Michael W., et al.
Publicado: (2018)

Engineering CAR-NK cells: how to tune innate killer cells for cancer immunotherapy
por: Schmidt, Dayane, et al.
Publicado: (2022)

Prolonged contact with dendritic cells turns lymph node‐resident NK cells into anti‐tumor effectors
por: Mingozzi, Francesca, et al.
Publicado: (2016)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Renaissance of armored immune effector cells, CAR-NK cells, brings the higher hope for successful cancer therapy
por: Marofi, Faroogh, et al.
Publicado: (2021)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Turn to TCRs when CARs fail
por: Stauss, Hans J.
Publicado: (2017)

NK cells engineered to express a GD(2)-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
por: Esser, Ruth, et al.
Publicado: (2012)

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas
por: Burger, Michael C., et al.
Publicado: (2017)

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)

Editorial: Translating NK cell scientific research to clinical product manufacturing
por: Ullrich, Evelyn, et al.
Publicado: (2023)

EGFR-Targeted Granzyme B Expressed in NK Cells Enhances Natural Cytotoxicity and Mediates Specific Killing of Tumor Cells
por: Oberoi, Pranav, et al.
Publicado: (2013)

Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy
por: Kilgour, Marisa K., et al.
Publicado: (2023)

Importance of T, NK, CAR T and CAR NK Cell Metabolic Fitness for Effective Anti-Cancer Therapy: A Continuous Learning Process Allowing the Optimization of T, NK and CAR-Based Anti-Cancer Therapies
por: Krug, Adrien, et al.
Publicado: (2021)

CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
por: Han, Jianfeng, et al.
Publicado: (2015)

Ventriculoperitoneal Shunts Equipped with On-Off Valves for Intraventricular Therapies in Patients with Communicating Hydrocephalus due to Leptomeningeal Metastases
por: Burger, Michael C., et al.
Publicado: (2018)

Activation of Epidermal Growth Factor Receptor Sensitizes Glioblastoma Cells to Hypoxia-Induced Cell Death
por: Luger, Anna-Luisa, et al.
Publicado: (2020)

Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021)

CAR-NK Cells in the Treatment of Solid Tumors
por: Wrona, Ewa, et al.
Publicado: (2021)

Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
por: Heipertz, Erica L., et al.
Publicado: (2021)

Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions
por: Sajman, Julia, et al.
Publicado: (2023)

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany
por: Albinger, Nawid, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f1cip1r3c5ef8fggapf1328n9a